SUMMIT THERAPEUTICS INC (SMMT)
US86627T1088 - Common Stock
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Prediction: These 3 Healthcare Stocks Will Soar in 2025
3 Stocks That Could Be Monster Winners in 2025
Where Will Summit Therapeutics Be in 5 Years?
3 Stocks That Could Turn $1,000 into $5,000 by 2030
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. BTIG analyst Justin Zelin thinks Viking Therapeutics stock can reach $125 per share for a gain of about 166% over the next 12 months. If an experimental weight loss treatment it's developing continues to succeed in clinical trials, the stock could more than double again.
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
While chipmaker Nvidia is an obvious example of a top growth stock to own given its more than 2,500% return over the past five years, there are many other stocks that have produced incredible gains in a short stretch. Three stocks that have done phenomenally well this year and have outperformed Nvidia are AppLovin (NASDAQ: APP), MicroStrategy (NASDAQ: MSTR), and Summit Therapeutics (NASDAQ: SMMT). If you invested $5,000 into each one of these stocks at the beginning of the year, the total of those investments would be worth more than $100,000 right now.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Summit Therapeutics Larger Than S&P 500 Component Campbell's
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Warning: This Skyrocketing Stock Has a Hidden Risk
Summit Therapeutics to Present at Upcoming Investor Conferences
3 Monster Stocks in the Making
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China.
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
If you're patient, these businesses have a lot of promising projects in the works.
Why Summit Therapeutics Stock Was a Winner Today
A cancer drug has vast potential for the company, says a pundit newly following it.
3 Magnificent Stocks Under $100 to Buy in November
The price could be right for these stocks.
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night.
Commit To Purchase Summit Therapeutics At $12, Earn 23.8% Using Options
3 Stocks That Have Generated 1,000% Returns in Just 2 Years
Should you add these fast-growing stocks to your portfolio?
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
Is Summit Therapeutics a Millionaire Maker?
The potential upside of this stock is undeniably meaty.
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy.
